Drug resistance at start of treatment of all patients with culture-confirmed pulmonary multi-drug-resistant (MDR)-tuberculosis (TB), extensively drug-resistant (XDR)-TB and non-MDR-TB starting TB treatment in Estonia from January 2003 to December 2005
| MDR-TB | XDR-TB | Non-MDR-TB | |
| Subjects n | 235 | 54 | 872 |
| First-line drugs | |||
| Isoniazid | 235 (100.0) | 54 (100.0) | 106 (12.2) |
| Rifampicin | 235 (100.0) | 54 (100.0) | 2 (0.2) |
| Streptomycin | 220 (93.6) | 49 (90.7) | 141 (16.2) |
| Pyrazinamide | 63 (26.8) | 13 (24.1) | 4 (0.5) |
| Ethambutol | 215 (91.5) | 53 (98.1) | 19 (2.2) |
| To all first line drugs | 186 (79.1) | 46 (85.2) | 0 (0) |
| Second-line drugs | |||
| Amikacin | 32 (13.6) | 15 (27.8) | 4 (0.5) |
| Capreomycin | 34 (14.5) | 11 (20.4) | 4 (0.5) |
| Kanamycin | 153 (65.1) | 53 (98.1) | 7 (0.8) |
| Ofloxacin | 68 (28.9) | 54 (100.0) | 4 (0.5) |
| Protionamide | 64 (27.2) | 20 (37.0) | 23 (2.6) |
Data are presented as n (%), unless otherwise stated.